Biological Drugs Volume 1 (el. knyga) (skaityta knyga) | knygos.lt

Aprašymas

Biological drugs have revolutionized modern medicine, providing highly effective therapies for cancer, autoimmune diseases, genetic disorders, infectious diseases, and many other serious conditions. Their successful development, however, requires mastery of complex scientific principles, advanced manufacturing technologies, and an increasingly demanding global regulatory environment. This volume provides a comprehensive, practical guide to the development of both innovative biological products and biosimilars, covering every stage from product design and process development to manufacturing, quality assurance, regulatory submission, and commercialization.

Drawing upon decades of scientific, industrial, and regulatory experience, the book explains how to establish efficient development strategies that reduce time, cost, and technical risk without compromising product quality or regulatory compliance. Numerous examples of electronic Common Technical Document (eCTD) submissions, development plans, manufacturing workflows, and regulatory documentation illustrate internationally accepted best practices and demonstrate how sound scientific principles can be translated into successful product development.

Comprehensive appendices summarize the regulatory dossiers and development pathways for virtually every major class of approved biological drugs, providing practical guidance for selecting appropriate development strategies and preparing scientifically justified submissions. Particular emphasis is placed on distinguishing essential regulatory expectations from unnecessary studies and common misconceptions that frequently increase development costs and delay market entry.

Combining scientific depth with practical implementation, this volume serves as an authoritative reference for scientists, engineers, manufacturers, regulatory professionals, biotechnology entrepreneurs, and graduate students engaged in the research, development, manufacture, and approval of biological medicines worldwide.

Key Features

• Outlines the history of technology and evolution of biological drugs, emphasizing the trends in the changes expected over the next two decades.
• Describes the development of novel biological drugs, types of drugs, their mode of action, the hurdles in identifying and developing them.
• Creates practical manufacturing processes with novelty in mind; for example, recombinant may soon be replaced by cell-free or mRNA? Detailed discussions of all technologies are provided.
• Discusses establishment of GMP-compliant manufacturing, from facility design to qualification with emphasis on multiple-use options.
• Provides examples of classes of biological drugs from therapeutic proteins to vaccines and gene therapies as well as examples of eCTDs for over 50 biological drugs.